PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2634.20%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-468.26%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-263.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-197.18%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-197.18%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
22.83%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
22.83%
Diluted share reduction more than 1.5x GNPX's 80.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-36.01%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-62.21%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-319.11%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-319.11%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
52.30%
3Y OCF/share CAGR at 50-75% of GNPX's 96.26%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-5305.80%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5305.80%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-47.53%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-1146.88%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1146.88%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
3.51%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while GNPX shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.29%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
10.32%
Debt growth of 10.32% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
402.37%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.